Lv1
50 积分 2022-06-15 加入
Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets
16小时前
待确认
Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer
16天前
已关闭
Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair–Deficient Colon Cancer
8个月前
已关闭
A model for RAS mutation patterns in cancers: finding the sweet spot
9个月前
已完结
Glue-based KRAS inhibitors make their debut cancer trial mark
1年前
已完结
The energetic and allosteric landscape for KRAS inhibition
1年前
已完结
951, JULY 2023Download Full Issue Purchase Subscribe Save Share Reprints Request D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results
1年前
已完结
A model for RAS mutation patterns in cancers: finding the sweet spot
1年前
已完结
Targeting cancer with molecular glues
1年前
已完结
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
1年前
已完结
皖公网安备34019202002308
